Ozomet-VG 2 Tablet PR

Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering improved glycemic regulation. Ozomet-VG 2 Tablet PR is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents.

It should be administered under medical supervision, with dosage adjustments based on glycemic response and tolerance. Caution is advised in patients with renal or hepatic impairment, and monitoring for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis is essential. This combination therapy supports comprehensive diabetes management, aiming to reduce the risk of microvascular and macrovascular complications.